Zacks: Brokerages Expect Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) to Announce -$1.65 EPS

Share on StockTwits

Brokerages predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post earnings per share (EPS) of ($1.65) for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Ultragenyx Pharmaceutical’s earnings. The lowest EPS estimate is ($1.96) and the highest is ($1.46). Ultragenyx Pharmaceutical reported earnings per share of ($1.73) during the same quarter last year, which would suggest a positive year over year growth rate of 4.6%. The company is expected to report its next quarterly earnings report on Tuesday, February 18th.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($7.16) per share for the current financial year, with EPS estimates ranging from ($7.46) to ($6.95). For the next year, analysts anticipate that the firm will report earnings of ($5.72) per share, with EPS estimates ranging from ($7.30) to ($2.21). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.71) by ($0.25). The business had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $28.88 million. Ultragenyx Pharmaceutical had a negative net margin of 470.18% and a negative return on equity of 52.16%. The business’s quarterly revenue was up 119.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.74) earnings per share.

Several equities analysts have recently commented on the company. Piper Jaffray Companies set a $75.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Wednesday, September 4th. Morgan Stanley reduced their price objective on Ultragenyx Pharmaceutical from $79.00 to $76.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Leerink Swann restated a “positive” rating and set a $85.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, September 4th. JPMorgan Chase & Co. restated a “buy” rating and set a $75.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, November 6th. Finally, Barclays restated a “buy” rating and set a $87.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Sunday, August 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $71.92.

Shares of Ultragenyx Pharmaceutical stock traded up $0.20 on Wednesday, hitting $37.28. 401,800 shares of the company’s stock traded hands, compared to its average volume of 543,912. The stock has a market cap of $2.25 billion, a P/E ratio of -5.04 and a beta of 2.15. The company has a quick ratio of 6.64, a current ratio of 6.79 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average is $41.64 and its 200 day moving average is $53.91. Ultragenyx Pharmaceutical has a 52-week low of $36.13 and a 52-week high of $74.50.

In related news, CEO Emil D. Kakkis bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were bought at an average cost of $43.63 per share, for a total transaction of $218,150.00. Following the completion of the purchase, the chief executive officer now owns 472,479 shares of the company’s stock, valued at approximately $20,614,258.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Ultragenyx Pharmaceutical by 2.3% in the second quarter. Vanguard Group Inc. now owns 5,005,872 shares of the biopharmaceutical company’s stock valued at $317,874,000 after buying an additional 112,101 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Ultragenyx Pharmaceutical by 31.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 4,611,939 shares of the biopharmaceutical company’s stock valued at $292,858,000 after buying an additional 1,110,316 shares during the last quarter. Macquarie Group Ltd. lifted its stake in Ultragenyx Pharmaceutical by 19.6% in the second quarter. Macquarie Group Ltd. now owns 797,293 shares of the biopharmaceutical company’s stock valued at $50,628,000 after buying an additional 130,561 shares during the last quarter. Northern Trust Corp lifted its stake in Ultragenyx Pharmaceutical by 5.0% in the second quarter. Northern Trust Corp now owns 691,110 shares of the biopharmaceutical company’s stock valued at $43,886,000 after buying an additional 32,812 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Ultragenyx Pharmaceutical by 5.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 318,418 shares of the biopharmaceutical company’s stock valued at $20,220,000 after buying an additional 17,415 shares during the last quarter.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Read More: Institutional Investors

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.